EverSource Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

EverSource Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.1K	Sell	372 -140	-27%	-$30.4K	﹤0.01%	1436
2026 Q1	$86.5K	Buy	512 +166	+48%	+$28.7K	﹤0.01%	1523
2025 Q4	$63.2K	Sell	346 -9	-3%	-$1.26K	﹤0.01%	1594
2025 Q3	$43.1K	Buy	355 +41	+13%	+$4.62K	﹤0.01%	1805
2025 Q2	$32.8K	Buy	314 +55	+21%	+$5.82K	﹤0.01%	1922
2025 Q1	$30.2K	Buy	259 +81	+46%	+$9.23K	﹤0.01%	1476
2024 Q4	$15.1K	Buy	178 +58	+48%	+$5.33K	﹤0.01%	1784
2024 Q3	$10.8K	Buy	120 +2	+2%	+$175	﹤0.01%	1819
2024 Q2	$10.3K	Buy	118 +99	+521%	+$7.33K	﹤0.01%	1840
2024 Q1	$1.4K	Sell	19 -43	-69%	-$3.61K	﹤0.01%	2480
2023 Q4	$4.93K	Buy	+62	New	+$4.14K	﹤0.01%	1866

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EverSource Wealth Advisors's AXSM Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Axsome Therapeutics (AXSM) stake by 27% in Q2 2026, selling an estimated $30.4K and leaving 372 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

EverSource Wealth Advisors first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

EverSource Wealth Advisors held 372 shares of Axsome Therapeutics worth $91.1K as of Q2 2026.
EverSource Wealth Advisors sold 140 Axsome Therapeutics shares in Q2 2026, an estimated $30.4K.
Axsome Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1436 holding.
EverSource Wealth Advisors first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.